This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
According to recent research from Australia, Evidence that activating mutations of the KRAS oncogene abolish the response to anti-epidermal growth factor receptor therapy has revolutionized the treatment of advanced colorectal cancer. This has resulted in the urgent demand for KRAS mutation testing in the clinical setting to aid choice of therapy.
We care about your feedback. Let us know how we can improve your CancerCompass experience.